Literature DB >> 30499591

Recent and occult hepatitis B virus infections among blood donors in the United States.

Sumathi Ramachandran1, Jamel A Groves2, Guo-Liang Xia1, Paula Saá2, Edward P Notari2, Jan Drobeniuc1, Amanda Poe1, Natasha Khudyakov1, Sarah F Schillie1, Trudy V Murphy1, Saleem Kamili1, Chong-Gee Teo1, Roger Y Dodd2, Yury E Khudyakov1, Susan L Stramer2.   

Abstract

BACKGROUND: Characteristics of US blood donors with recent (RBI) or occult (OBI) hepatitis B virus (HBV) infection are not well defined.
METHODS: Donors with RBI and OBI were identified by nucleic acid and serologic testing among 34.4 million donations during 2009-2015. Consenting donors were interviewed and their HBV S-gene sequenced.
RESULTS: The overall rate of HBV-infected donors was 7.95 per 100,000; of these, 0.35 per 100,000 and 1.70 per 100,000 were RBI and OBI, respectively. RBI (n = 120) and OBI (n = 583) donors constituted 26% of all HBV-infected (n = 2735) donors. Detection of HBV DNA in 92% of OBI donors required individual donation nucleic acid testing. Donors with OBI compared to RBI were older (mean age, 48 vs 39 years; p < 0.0001) with lower median viral loads (9 vs. 529 IU/mL; p < 0.0001). A higher proportion of OBI than RBI donors were born or resided in an endemic country (39% vs. 5%; p = 0.0078). Seventy-seven percent of all RBI and OBI donors had multiple sex partners, an HBV-risk factor. Of 40 RBI and 10 OBI donors whose S gene was sequenced, 33 (83%) and 6 (60%), respectively, carried HBV subgenotype A2; 18 (55%) and 2 (33%), respectively, shared an identical sequence. Infection with 1 or more putative HBV-immune-escape mutants was identified in 5 (50%) of OBI but no RBI donors.
CONCLUSION: RBI and OBI continue to be identified at low rates, confirming the importance of comprehensive HBV DNA screening of US blood donations. HBV-infected donors require referral for care and evaluation and contact tracing; their HBV strains may provide important information on emergent genotypes.
© 2018 AABB.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30499591      PMCID: PMC8190636          DOI: 10.1111/trf.15057

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  31 in total

1.  Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection.

Authors:  Subhajit Biswas; Daniel Candotti; Jean-Pierre Allain
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

2.  Analytical and clinical performance evaluation of the cobas TaqScreen MPX Test for use on the cobas s 201 system.

Authors:  Yosh Ohhashi; Anuradha Pai; Harkanwal Halait; Rainer Ziermann
Journal:  J Virol Methods       Date:  2010-02-10       Impact factor: 2.014

3.  High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum.

Authors:  K M Weinberger; T Bauer; S Böhm; W Jilg
Journal:  J Gen Virol       Date:  2000-05       Impact factor: 3.891

4.  Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations.

Authors:  Lynn A Martin; Susan L Stramer; Mary C Kuhns; George G Schlauder
Journal:  Transfusion       Date:  2012-02-10       Impact factor: 3.157

Review 5.  Hepatitis B mother--to--child transmission.

Authors:  Sylvie Ranger-Rogez; François Denis
Journal:  Expert Rev Anti Infect Ther       Date:  2004-02       Impact factor: 5.091

6.  Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012.

Authors:  Henry Roberts; Deanna Kruszon-Moran; Kathleen N Ly; Elizabeth Hughes; Kashif Iqbal; Ruth B Jiles; Scott D Holmberg
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

7.  The efficacy of individual-donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan.

Authors:  Meng-Hua Yang; Lei Li; Ying-Shen Hung; Cheng-Shen Hung; Jean-Pierre Allain; Kuo-Sin Lin; Su-Jen Lin Tsai
Journal:  Transfusion       Date:  2009-08-26       Impact factor: 3.157

8.  Hepatitis B virus genotypes in the United States: results of a nationwide study.

Authors:  Chi-Jen Chu; Emmet B Keeffe; Steven-Huy Han; Robert P Perrillo; Albert D Min; Consuelo Soldevila-Pico; William Carey; Robert S Brown; Velimir A Luketic; Norah Terrault; Anna S F Lok
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

9.  Infectivity of blood products from donors with occult hepatitis B virus infection.

Authors:  Jean-Pierre Allain; Ivanka Mihaljevic; Maria Isabel Gonzalez-Fraile; Knut Gubbe; Lene Holm-Harritshøj; Jose Maria Garcia; Ewa Brojer; Christian Erikstrup; Mona Saniewski; Lorenz Wernish; Lydia Bianco; Henrik Ullum; Daniel Candotti; Nico Lelie; Wolfram H Gerlich; Michael Chudy
Journal:  Transfusion       Date:  2013-01-30       Impact factor: 3.157

10.  Comparison of seven hepatitis B virus (HBV) nucleic acid testing assays in selected samples with discrepant HBV marker results from United States blood donors.

Authors:  Florence Enjalbert; David E Krysztof; Daniel Candotti; Jean-Pierre Allain; Susan L Stramer
Journal:  Transfusion       Date:  2014-04-17       Impact factor: 3.157

View more
  2 in total

Review 1.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

2.  Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain.

Authors:  Rocío González; Luisa Barea; Ana Arruga; Alberto Richart; Vicente Soriano
Journal:  Ther Adv Infect Dis       Date:  2020-12-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.